Prelude Therapeutics PRLD
NASDAQ PRLD
$3.91 -0.05 (-1.26%)
At close: Sep 30, 2026 · 4:00 PM EDT

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026)

Updated

Prelude Therapeutics (PRLD) posted EBIT Margin of -270.93% for Q2 2026, up 38.61 percentage points from the prior quarter.

Analysis

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBIT Margin at Prelude Therapeutics was -300.56%, up 1628.11 percentage points year-over-year; for FY2025, it was -861.33%, up 1134.58 percentage points from FY2024.

  • In prior years, Prelude Therapeutics' EBIT Margin was -1995.91% in FY2024.
  • According to Business Quant data, EBIT Margin for the three prior quarters was -309.54% (Q1 2026), -307.59% (Q4 2025) and -314.12% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 Prelude Therapeutics 312.03 Mn -285.27 Mn - -270.93%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -270.93%
Mar 31, 2026 -309.54%
Dec 31, 2025 -307.59%
Sep 30, 2025 -314.12%
Dec 31, 2024 -845.78%
Sep 30, 2024 -1,145.87%
API Access

Prelude Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=PRLD&period=max&api_key=YOUR_API_KEY